[go: up one dir, main page]

WO2004096792A3 - Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr - Google Patents

Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr Download PDF

Info

Publication number
WO2004096792A3
WO2004096792A3 PCT/FR2004/000979 FR2004000979W WO2004096792A3 WO 2004096792 A3 WO2004096792 A3 WO 2004096792A3 FR 2004000979 W FR2004000979 W FR 2004000979W WO 2004096792 A3 WO2004096792 A3 WO 2004096792A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
ny1y2
denotes
pharmaceutical compositions
indole derivatives
Prior art date
Application number
PCT/FR2004/000979
Other languages
English (en)
Other versions
WO2004096792A2 (fr
Inventor
Antonio Ugolini
Herve Bouchard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Priority to EP04742556A priority Critical patent/EP1633738A2/fr
Priority to JP2006505807A priority patent/JP2006524668A/ja
Publication of WO2004096792A2 publication Critical patent/WO2004096792A2/fr
Publication of WO2004096792A3 publication Critical patent/WO2004096792A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne les produits de formule (I): dans laquelle R1 représente pyrazolyle ou indazolyle, R2 et R3 représentent notamment H, halogène, hydroxyle, nitro, cyano, R4, -OR4, -COR4, -OC(=O)R4, -C(=O)OR4, C(=O)OH, -N(R5)C(=O)R4, -N(R5)C(=O)OR4, -S(O)nR4, S(O)nOR4, -N(R5)SO2R4, -NY1Y2, -C(=O)NY1Y2, N(R5)C(=O)NY1Y2, -S(O)nNY1Y2 et -OC(=O)NY1Y2, R4 représente notamment alkyle, alkényle, cycloalkyle, aryle, hétéroaryle, hétérocycloalkyle, R5 représente notamment H, alkyle, alkényle, cycloalkyle, hétérocycloalkyle, aryle, hétéroaryle, Y1 et Y2 représentent notamment H, alkyle, alkényle, cycloalkyle, hétérocycloalkyle, aryle, arylcarboxy, hétéroaryle et hétéroarylcarboxy, étant éventuellement substitués, soit Y1 et Y2 forment avec N un cycle aminé, n représente 0 à 2, tous ces radicaux étant éventuellement substitués, ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments notamment comme inhibiteurs de KDR.
PCT/FR2004/000979 2003-04-25 2004-04-22 Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr WO2004096792A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04742556A EP1633738A2 (fr) 2003-04-25 2004-04-22 Nouveaux derives de l indole, leur preparation a titre de me dicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
JP2006505807A JP2006524668A (ja) 2003-04-25 2004-04-22 新規なインドール誘導体、ならびに医薬物質および医薬組成物、特にｋｄｒ阻害剤としてのそれらの製造法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR03/05088 2003-04-25
FR0305088A FR2854159B1 (fr) 2003-04-25 2003-04-25 Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr

Publications (2)

Publication Number Publication Date
WO2004096792A2 WO2004096792A2 (fr) 2004-11-11
WO2004096792A3 true WO2004096792A3 (fr) 2005-09-15

Family

ID=33104394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/000979 WO2004096792A2 (fr) 2003-04-25 2004-04-22 Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr

Country Status (4)

Country Link
EP (1) EP1633738A2 (fr)
JP (1) JP2006524668A (fr)
FR (1) FR2854159B1 (fr)
WO (1) WO2004096792A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2008501628A (ja) * 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
WO2007077435A1 (fr) * 2005-12-30 2007-07-12 Astex Therapeutics Limited Composes pharmaceutiques
US8435970B2 (en) * 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
KR101529767B1 (ko) 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 아미노피라졸 유도체
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
DK3087986T3 (da) 2013-12-27 2019-12-02 Chugai Pharmaceutical Co Ltd Mutant fgfr-gatekeepergen og aktivt stof rettet mod samme
WO2016204261A1 (fr) 2015-06-17 2016-12-22 中外製薬株式会社 Dérivés d'aminopyrazole
WO2019126081A1 (fr) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Composés d'indole à substitution amide utiles en tant qu'inhibiteurs de tlr
WO2021154902A1 (fr) * 2020-01-30 2021-08-05 Anima Biotech Inc. Inhibiteurs de traduction de collagène 1 et leurs procédés d'utilisation
CN116332912A (zh) * 2023-03-02 2023-06-27 广西大学 一种2-氨基-5-硫基吲哚类衍生物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (fr) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
WO2003024969A1 (fr) * 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs des tyrosine kinases
FR2831537A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001122855A (ja) * 1999-10-27 2001-05-08 Japan Tobacco Inc インドール化合物及びその医薬用途
MXPA02010222A (es) * 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (fr) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
WO2003024969A1 (fr) * 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs des tyrosine kinases
FR2831537A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VLADIMIR V ROZHKOV ET AL: "Synthesis of 2-aryl- and 2-hetaryl-4,6-dinitroindoles from 2,4,6-trinitrotoluene", SYNTHESIS, GEORG THIEME VERLAG. STUTTGART, DE, vol. 12, 1999, pages 2065 - 2070, XP002187465, ISSN: 0039-7881 *

Also Published As

Publication number Publication date
EP1633738A2 (fr) 2006-03-15
FR2854159A1 (fr) 2004-10-29
WO2004096792A2 (fr) 2004-11-11
JP2006524668A (ja) 2006-11-02
FR2854159B1 (fr) 2008-01-11

Similar Documents

Publication Publication Date Title
WO2004096792A3 (fr) Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
HRP20020926B1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
WO2005123731A3 (fr) Composes organiques
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
HUP0400561A2 (hu) 3-Aroilindol-származékok és a vegyületek CB2 receptor agonistaként való alkalmazása, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
WO2010007316A3 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
ATE407151T1 (de) In kaltem wasser lösliches -g(b)-glukanprodukt und verfahren zu dessen herstellung
WO2010007318A3 (fr) NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
DE602004019814D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren anwendungen
TW200626553A (en) Novel compounds
MXPA05007519A (es) Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
WO2003072576A3 (fr) Composes chimiques
SE0401763D0 (sv) Compounds
HUP9700708A2 (hu) N-[(9-pirimido[1,2-a]indolil)-metil-fenil-acetil]-fenil-glicinol-származékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és intermedierjeik
WO2005000840A8 (fr) Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine
GEP20115240B (en) Indole derivatives, process for their preparation and pharmaceutical compositions containing them
CA2278687A1 (fr) Derives de 5-aroylnaphthalene
WO2003076426A3 (fr) Composes therapeutiques
MXPA04005837A (es) Nuevos derivados de benzotiazina y benzotiadiazina, metodo para su preparacion y composiciones farmaceuticas que los contienen.
WO2005095399A3 (fr) Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MY113529A (en) New derivatives of imidazole n- benzyldioxole,processes for their preparation, their use as medicaments and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004742556

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006505807

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004742556

Country of ref document: EP